---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-000480"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:25:07.629100+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arrowhead prices 15.79M share offering at $28.50, expects net proceeds of $429.0M

## Summary
- Sales of 15,790,000 shares at $28.50/share; net proceeds ~$429.0M after discounts and expenses.
- Underwriters include Jefferies, BofA Securities, and Cowen and Company as representatives.
- Proceeds allocated to R&D, general corporate expenses, and working capital needs.
- Offering expected to close on January 5, 2024, subject to customary conditions.

## SEC filing metadata
- accession: 0001628280-24-000480
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828024000480/0001628280-24-000480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828024000480/arwr-20240102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-000480
- JSON: https://secwatch.observer/filing/0001628280-24-000480.json
- Plain text: https://secwatch.observer/filing/0001628280-24-000480.txt

## Key facts
- Material Agreements
  ARROWHEAD PHARMACEUTICALS, INC. entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the several underwriters valued at approximately $429.0 million (effective 2024-01-02).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the several underwriters
  - Value: approximately $429.0 million
  - Effective: 2024-01-02
  source text: On January 2, 2024, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the several underwriters (the “Underwriters”), pursuant to which the Company agreed to issue and sell 15,790,000 shares of the Company’s common stock (the “Shares”), par value $0.001 per share at an offering price of $28.50 per Share (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828024000480/0001628280-24-000480-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.